Drug intelligence / Profile preview

IPN-59011

Development stage: Phase 1
Lead developer: Ipsen
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Intramuscular

Overview

IPN-59011 is a novel neurotoxin developed by Ipsen for the treatment of moderate to severe upper facial lines (facial wrinkles). It acts as an antagonist of the acetylcholine receptor (AChR), specifically targeting the nAChR alpha1, beta1, delta, and gamma subunits. The drug was designed to have a longer duration of action compared to currently marketed products for facial wrinkle reduction. Its development reached up to Phase 2 clinical trials but has since been discontinued[1][2][7].

Targets

Muscle-type nicotinic acetylcholine receptor

Beyond the preview

Go deeper on IPN-59011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IPN-59011.

Explore the full profile